Neuropsychiatric Disorders An Integrative Approach

1. The meeting of minds and times with Peter Riederer: an appreciation
M. B. H. Youdim

2. Succi nervorum: a brief history of neurochemistry
P. Foley

3. Neuronal differentiation and long-term culture of the human neuroblastoma line SH-SY5Y
R. Constantinescu, A. T. Constantinescu, H. Reichmann, B. Janetzky

4. Endogenous oxidized indoles share inhibitory potency against [3H]isatin binding in rat brain
M. Crumeyrolle-Arias, A. Medvedev, A. Cardona, M.-C. Tournaire, V. Glover

5. Lipid content determines aggregation of neuromelanin granules in vitro
V. N. Dedov, F. M. Griffiths, B. Garner, G. M. Halliday, K. L. Double

6. Hydrogen peroxide is a true first messenger
L. Holmquist, G. Stuchbury, M. Steele, G. Münch

7. The therapeutic potential of siRNA in gene therapy of neurodegenerative disorders
E. Koutsilieri, A. Rethwilm, C. Scheller

8. Tyrosinase is not detected in human catecholaminergic neurons by immunohistochemistry and Western blot analysis
F. Tribl, T. Arzberger, P. Riederer, M. Gerlach

9. Luteolin protects rat PC 12 and C6 cells against MPP+ induced toxicity via an ERK dependent Keapl-Nrf2-ARE pathway
C. J. Wruck, M. Claussen, G. Fuhrmann, L. Römer, A. Schulz, T. Pufe, V. Waetzig, M. Peipp, T. Herdegen, M. E. Götz

10. Behavioural and expressional phenotyping of nitric oxide synthase-I knockdown animals
T. Wultsch, S. Chourbaji, S. Fritzen, S. Kittel, E. Grünblatt, M. Gerlach, L. Gutknecht, F. Chizat, G. Golfler, A. Schmitt, P. Gass, K.-P. Lesch, A. Reif

11. Animal models in neurodegenerative diseases
E. C. Hirsch

12. Morphological substrates of parkinsonism with and without dementia: a retrospective clinico-pathological study
K. A. Jellinger

13. Ginsenoside Rd attenuates neuroinflammation of dopaminergic cells in culture
W.-M. Lin, Y.-M. Zhang, R. Moldzio, W.-D. Rausch

14. Biochemistry of postmortem brains in Parkinson’s disease: historical overview and future prospects
T. Nagatsu, M. Sawada

15. Neuroprotection by propargylamines in Parkinson’s disease: intracellular mechanism underlying the anti-apoptotic function and search for clinical markers
M. Naoi, W. Maruyama, H. Yi, Y. Akao, Y. Yamaoka, M. Shamoto-Nagai

16. Intrastriatal transplantation of mouse bone marrow-derived stem cells improves motor behavior in a mouse model of Parkinson’s disease
D. Offen, Y. Barhum, Y.-S. Levy, A. Burshtein, H. Panet, T. Cherlow, E. Melamed

17. Low dose methylphenidate improves freezing in advanced Parkinson’s disease during off-state
L. Pollak, Y. Dobronevsky, T. Prohorov, S. Bahunker, J. M. Rabey

18. The long-term effects of the neurotoxin l-trichloromethyl-1,2,3,4-tetrahydro-ß-carboline (TaClo) on cognitive performance in rats
T. A. Sontag, K. W. Lange, Ch. Heim, W. Kolasiewicz, O. Tucha, K.-H. Sontag

19. Observations on the cortical silent period in Parkinson’s disease
Y. D. Werf, H. W. Berendse, E. J. W. Someren, D. Stoffers, C. J. Stam, E. Ch. Wolters

20. CYP 2E1 mutant mice are resistant to DDC-induced enhancement of MPTP toxicity
C. Viaggi, F. Vaglini, C. Pardini, P. Sgadó, A. Caramelli, G. U. Corsini

21. Pharmacokinetic studies of (—)-deprenyl and some of its metabolites in mouse
K. Magyar, I. Szatmáry, G. Szebeni, J. Lengyel

22. Serum lipoprotein profile and APOE genotype in Alzheimer’s disease
A. Cagnin, A. Zambon, G. Zarantonello, D. Vianello, M. Marchiori, D. Mercurio, F. Miccichè, M. Ermani, A. Leon, L. Battistin

23. VITA study: white matter hyperintensities of vascular and degenerative origin in the elderly
P. Fischer, W. Krampla, N. Mostafaie, S. Zehetmayer, M. Rainer, S. Jungwirth, K. Huber, K. Bauer, W. Hruby, P. Riederer, K. H. Tragl

24. a-Lipoic acid as a new treatment option for Alzheimer’s disease — a 48 months follow-up analysis
K. Hager, M. Kenklies, J. McAfoose, J. Engel, G. Münch

25. Long-term abnormalities in brain glucose/energy metabolism after inhibition of the neuronal insulin receptor: implication of tau-protein
S. Hoyer, H. Lannert

26. Long-term tetrahydroaminoacridine treatment and quantitative EEG in Alzheimer’s disease
E. A. Kogan, R. G. Verchovsky, M. Y. Neufeld, S. Sh. Klimovitsky, T. A. Treves, A. D. Korczyn

27. Enhanced apoptosis, oxidative stress and mitochondrial dysfunction in lymphocytes as potential biomarkers for Alzheimer’s disease
K. Leuner, J. Pantel, C. Frey, K. Schindowski, K. Schulz, T. Wegat, K. Maurer, A. Eckert, W. E. Müller

28. Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: an experimental approach
M. Salkovic-Petrisic, S. Hoyer

29. Brain antioxidant capacity in rat models of betacytotoxic-induced experimental sporadic Alzheimer’s disease and diabetes mellitus
I. Tahirovic, E. Sofic, A. Sapcanin, I. Gavrankapetanovic, L. Bach-Rojecky, M. Salkovic-Petrisic, Z. Lackovic, S. Hoyer, P. Riederer

30. Improving linear modeling of cognitive decline in patients with mild cognitive impairment: comparison of two methods
S. J. Teipel, A. J. Mitchell, H.-J. Möller, H. Hampel

31. Interaction of attention and graphomotor functions in children with attention deficit hyperactivity disorder
K. W. Lange, L. Tucha, S. Walitza, M. Gerlach, M. Linder, O. Tucha

32. Therapeutic drug monitoring of antidepressants — clinical aspects
G. Laux, P. Baumann, C. Hiemke, Bergemann N Heidelberg, Deckert J Würzburg, Dobmeier M Cham, Eckermann G Kaufbeuren, Gerlach M Würzburg, Haen E Regensburg, Jaquenoud-Sirot E Königsfelden, Köhnke M Rostock, Kuss HJ München, Messer T Augsburg, Pfuhlmann B Würzburg, Rao ML Bonn, Schoppek B Haar, Schwarz M München

33. The immunological basis of glutamatergic disturbance in schizophrenia: towards an integrated view
N. Müller, M. J. Schwarz

34. Deficits of neuronal glutamatergic markers in the caudate nucleus in schizophrenia
S. Nudmamud-Thanoi, P. Piyabhan, M.K. Harte, M. Cahir, G.P. Reynolds

35. Therapeutic drug monitoring of tricyclic antidepressants in everyday clinical practice
B. Pfuhlmann, M. Gerlach, R. Burger, S. Gonska, S. Unterecker, B. Jabs, P. Riederer, J. Deckert

36. FZD3 is not a risk gene for schizophrenia: a case-control study in a Caucasian sample
A. Reif, M. Melchers, A. Strobel, C. P. Jacob, S. Herterich, K.-P. Lesch, M. Zimmer

37. Impaired cortical inhibition in adult ADHD patients: a study with transcranial magnetic stimulation*
M. Schneider, W. Retz, C. Freitag, J. Irsch, P. Graf, P. Retz-Junginger, M. Rösier

38. Association of Parkinson’s disease with symptoms of attention deficit hyperactivity disorder in childhood
S. Walitza, S. Melfsen, G. Herhaus, P. Scheuerpflug, A. Warnke, T. Müller, K. W. Lange, M. Gerlach

39. Biostatistical analysis of gene microarrays reveals diverse expression clusters between macaque subspecies in brain SIV infection
S. Kneitz, F. Meisner, S. Sopper, F. Kaiser, E. Grünblatt, C. Scheller, P. Riederer, V. ter Meulen, E. Koutsilieri

40. Kynurenines, redox disturbances and neurodegeneration in multiple sclerosis
C. Rajda, J. Bergquist, L. Vécsei

41. Neural stem cell transplantation in a model of fetal alcohol effects
T. Yoshinaga, E. Hashimoto, W. Ukai, S. Toki, S. Saito, T. Saito

DRM-restrictions

Printing: not available
Clipboard copying: not available

Nyckelord: MEDICAL / Public Health MED078000